Ryo Ashida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryo Ashida has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
Katsuhiko Uesaka
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
48 shared publicationsKatsuhisa Ohgi
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
36 shared publications- Teiichi Sugiura
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
36 shared publications Shimpei Otsuka
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
28 shared publicationsTeiichi Sugiura
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
28 shared publications- Katsuhisa Ohgi
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan
26 shared publications
Latest Publications
- 13 August 2026
- Published by Wiley in Hepatology Research
Des‐Gamma‐Carboxy Prothrombin Is Associated With Tumor Aggressiveness and Recurrence in Resected Early‐Stage Hepatocellular Carcinoma: A Clinicopathological and Molecular Analysis
Aim: Alpha‐fetoprotein (AFP) and des‐gamma‐carboxy prothrombin (DCP) are widely used tumor markers for hepatocellular carcinoma (HCC); however, their relative prognostic significance in early‐stage disease remains unclear. This study aimed to compare the prognostic impact of AFP and DCP in resected HCC and to explore their underlying molecular characteristics. Methods: We retrospectively analyzed 482 patients who underwent curative resection for HCC. Patients were classified into four groups according to AFP and DCP levels: Negative, AFP‐only, DCP‐only, and Dual‐positive. Recurrence‐free survival (RFS) and prognostic factors were evaluated. In a subset of 204 patients, gene expression profiling was conducted to investigate molecular differences. Results: Among BCLC stage 0/A patients ( n = 406), RFS was stratified according to tumor marker status. The DCP‐only group showed significantly worse RFS than the AFP‐only group (5‐year RFS: 39.5% vs. 52.7%, p = 0.026) and was characterized by larger tumor size (median, 39 vs. 18 mm, p < 0.001) and more frequent portal venous invasion (29% vs. 14%, p = 0.052). Multivariable analysis identified elevated DCP as an independent prognostic factor (hazard ratio 1.48, p = 0.004). In contrast, among stage B/C patients ( n = 76), survival outcomes were uniformly poor and not stratified by tumor marker. Gene expression analysis revealed the upregulation of SFN and downregulation of DCN in DCP‐elevated tumors, suggesting extracellular matrix destabilization that may contribute to tumor aggressiveness. Conclusions: Elevated DCP reflects aggressive tumor biology and identifies patients at high risk of recurrence after resection for BCLC stage 0/A HCC. These findings support the clinical utility of DCP for risk stratification and postoperative surveillance for early‐stage HCC.
- 13 August 2026
- Published by Wiley in Hepatology Research
Des‐Gamma‐Carboxy Prothrombin Is Associated With Tumor Aggressiveness and Recurrence in Resected Early‐Stage Hepatocellular Carcinoma: A Clinicopathological and Molecular Analysis
Aim: Alpha‐fetoprotein (AFP) and des‐gamma‐carboxy prothrombin (DCP) are widely used tumor markers for hepatocellular carcinoma (HCC); however, their relative prognostic significance in early‐stage disease remains unclear. This study aimed to compare the prognostic impact of AFP and DCP in resected HCC and to explore their underlying molecular characteristics. Methods: We retrospectively analyzed 482 patients who underwent curative resection for HCC. Patients were classified into four groups according to AFP and DCP levels: Negative, AFP‐only, DCP‐only, and Dual‐positive. Recurrence‐free survival (RFS) and prognostic factors were evaluated. In a subset of 204 patients, gene expression profiling was conducted to investigate molecular differences. Results: Among BCLC stage 0/A patients ( n = 406), RFS was stratified according to tumor marker status. The DCP‐only group showed significantly worse RFS than the AFP‐only group (5‐year RFS: 39.5% vs. 52.7%, p = 0.026) and was characterized by larger tumor size (median, 39 vs. 18 mm, p < 0.001) and more frequent portal venous invasion (29% vs. 14%, p = 0.052). Multivariable analysis identified elevated DCP as an independent prognostic factor (hazard ratio 1.48, p = 0.004). In contrast, among stage B/C patients ( n = 76), survival outcomes were uniformly poor and not stratified by tumor marker. Gene expression analysis revealed the upregulation of SFN and downregulation of DCN in DCP‐elevated tumors, suggesting extracellular matrix destabilization that may contribute to tumor aggressiveness. Conclusions: Elevated DCP reflects aggressive tumor biology and identifies patients at high risk of recurrence after resection for BCLC stage 0/A HCC. These findings support the clinical utility of DCP for risk stratification and postoperative surveillance for early‐stage HCC.
- 27 July 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (8) , 7232-7233
Application of the Arantius-first approach in a patient with right-sided ligamentum teres
- 27 July 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (8) , 7232-7233
Application of the Arantius-first approach in a patient with right-sided ligamentum teres
- 20 July 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy
Objective: To evaluate the impact of CYP2A6 genetic polymorphisms on survival outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) receiving perioperative S-1 therapy. Background: S-1, an oral fluoropyrimidine containing tegafur, is widely used for perioperative treatment of PDAC in Japan. Tegafur requires metabolic activation to 5-fluorouracil, primarily by CYP2A6 . Given the high prevalence of reduced-function CYP2A6 variants in East Asian populations, their clinical significance in PDAC remains unclear. Methods: This retrospective study included 145 patients with PDAC who underwent curative resection and received adjuvant S-1, including 78 patients who had received S-1–containing neoadjuvant therapy. Germline CYP2A6 variants were identified using whole-exome sequencing of peripheral blood samples. Decreased-function alleles (*4, *7, *9) and the rare nonsense allele *48 were evaluated. Patients were classified into poor, intermediate, and normal metabolizer groups. Survival outcomes were analyzed using Kaplan-Meier and Cox regression analyses. Results: Decreased-function CYP2A6 genotypes were identified in 82 patients (56.6%), including 6 poor metabolizers (4.1%). These patients had a higher frequency of lymph node metastasis than those with normal genotypes (78.0% vs. 52.4%, P =0.001). Recurrence-free survival (RFS) was significantly shorter (median, 19.2 vs. 32.3 mo; P =0.040), whereas overall survival (OS) was shorter but not statistically significant (47.9 vs. 62.2 mo; P =0.104). In multivariable analysis, CYP2A6 poor metabolizer status was independently associated with OS (HR, 3.17; 95% CI, 1.06–9.46; P =0.039). Among the 78 patients who received S-1–containing neoadjuvant therapy, both OS and RFS were significantly worse in those with decreased-function genotypes. Conclusions: Decreased CYP2A6 functional genotypes were associated with poorer oncological outcomes in patients with PDAC receiving perioperative S-1 therapy, suggesting that the CYP2A6 genotype may serve as a biomarker for optimizing treatment strategies.
- 20 July 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy
Objective: To evaluate the impact of CYP2A6 genetic polymorphisms on survival outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) receiving perioperative S-1 therapy. Background: S-1, an oral fluoropyrimidine containing tegafur, is widely used for perioperative treatment of PDAC in Japan. Tegafur requires metabolic activation to 5-fluorouracil, primarily by CYP2A6 . Given the high prevalence of reduced-function CYP2A6 variants in East Asian populations, their clinical significance in PDAC remains unclear. Methods: This retrospective study included 145 patients with PDAC who underwent curative resection and received adjuvant S-1, including 78 patients who had received S-1–containing neoadjuvant therapy. Germline CYP2A6 variants were identified using whole-exome sequencing of peripheral blood samples. Decreased-function alleles (*4, *7, *9) and the rare nonsense allele *48 were evaluated. Patients were classified into poor, intermediate, and normal metabolizer groups. Survival outcomes were analyzed using Kaplan-Meier and Cox regression analyses. Results: Decreased-function CYP2A6 genotypes were identified in 82 patients (56.6%), including 6 poor metabolizers (4.1%). These patients had a higher frequency of lymph node metastasis than those with normal genotypes (78.0% vs. 52.4%, P =0.001). Recurrence-free survival (RFS) was significantly shorter (median, 19.2 vs. 32.3 mo; P =0.040), whereas overall survival (OS) was shorter but not statistically significant (47.9 vs. 62.2 mo; P =0.104). In multivariable analysis, CYP2A6 poor metabolizer status was independently associated with OS (HR, 3.17; 95% CI, 1.06–9.46; P =0.039). Among the 78 patients who received S-1–containing neoadjuvant therapy, both OS and RFS were significantly worse in those with decreased-function genotypes. Conclusions: Decreased CYP2A6 functional genotypes were associated with poorer oncological outcomes in patients with PDAC receiving perioperative S-1 therapy, suggesting that the CYP2A6 genotype may serve as a biomarker for optimizing treatment strategies.
- 13 May 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (9) , 1374-1381
Tumor Mutational Concordance and Recurrence Timing in Hepatocellular Carcinoma
Introduction: In hepatocellular carcinoma (HCC), intrahepatic recurrence includes true recurrence from clonal relapse and multicentric recurrence from de novo tumorigenesis. Recurrence timing is used to distinguish these types; however, its accuracy remains unclear. This study aimed to classify recurrent tumors based on somatic mutational concordance and assess the validity of recurrence timing. Methods: Whole‐exome sequencing was performed on paired primary and recurrent HCC tumors from 49 patients enrolled in a prospective institutional omics project. Tumors with ≥ 10 shared somatic mutations were classified as true recurrence. Clinicopathological features, recurrence timing, driver mutation patterns, and survival outcomes were compared between recurrence types. Mutational concordance was quantified using shared variant counts and the Jaccard similarity index. Results: Of the 49 patients, 22 (44.9%) showed true recurrence and 27 (55.1%) had multicentric recurrence. Multicentric recurrence tumors harbored no shared variants or only a single shared variant with the primary tumor. True recurrence was associated with significantly higher concordance in histological differentiation and Edmondson–Steiner grading and greater retention of CTNNB1 , TP53 , ARID1A , and KEAP1 mutations. The number of shared variants (median: 115 vs. 0, and p < 0.001) and the Jaccard index (median: 0.44 vs. 0.00 and p < 0.001) were significantly higher in the true recurrence group. Recurrence timing was inconsistently correlated with mutational concordance, although a 3‐year cutoff yielded significant separation. Conclusion: Recurrence timing alone insufficiently reflects clonal relationships. Genomic profiling offers a reliable framework for distinguishing between recurrence types and guiding HCC management.
- 13 May 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (9) , 1374-1381
Tumor Mutational Concordance and Recurrence Timing in Hepatocellular Carcinoma
Introduction: In hepatocellular carcinoma (HCC), intrahepatic recurrence includes true recurrence from clonal relapse and multicentric recurrence from de novo tumorigenesis. Recurrence timing is used to distinguish these types; however, its accuracy remains unclear. This study aimed to classify recurrent tumors based on somatic mutational concordance and assess the validity of recurrence timing. Methods: Whole‐exome sequencing was performed on paired primary and recurrent HCC tumors from 49 patients enrolled in a prospective institutional omics project. Tumors with ≥ 10 shared somatic mutations were classified as true recurrence. Clinicopathological features, recurrence timing, driver mutation patterns, and survival outcomes were compared between recurrence types. Mutational concordance was quantified using shared variant counts and the Jaccard similarity index. Results: Of the 49 patients, 22 (44.9%) showed true recurrence and 27 (55.1%) had multicentric recurrence. Multicentric recurrence tumors harbored no shared variants or only a single shared variant with the primary tumor. True recurrence was associated with significantly higher concordance in histological differentiation and Edmondson–Steiner grading and greater retention of CTNNB1 , TP53 , ARID1A , and KEAP1 mutations. The number of shared variants (median: 115 vs. 0, and p < 0.001) and the Jaccard index (median: 0.44 vs. 0.00 and p < 0.001) were significantly higher in the true recurrence group. Recurrence timing was inconsistently correlated with mutational concordance, although a 3‐year cutoff yielded significant separation. Conclusion: Recurrence timing alone insufficiently reflects clonal relationships. Genomic profiling offers a reliable framework for distinguishing between recurrence types and guiding HCC management.
- 17 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 6127
ASO-Author-Reflections: From Penetrative to Atraumatic—Redefining Retraction in Robotic Liver Surgery
- 17 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 6127
ASO-Author-Reflections: From Penetrative to Atraumatic—Redefining Retraction in Robotic Liver Surgery
- 5 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 6114
The Clip-Pulley Maneuver: Atraumatic and Adjustable Retraction in Robotic Liver Resection
Precise liver retraction is essential in robotic hepatectomy. Conventional retraction methods using barbed sutures1,2 or hook-needle systems3 are penetrati
- 5 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 6114
The Clip-Pulley Maneuver: Atraumatic and Adjustable Retraction in Robotic Liver Resection
Precise liver retraction is essential in robotic hepatectomy. Conventional retraction methods using barbed sutures1,2 or hook-needle systems3 are penetrati
- Open Access
- 13 March 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1309-1319
Impact of Recanalization on Liver Hypertrophy after Portal Vein Embolization and the Role of Re‐Embolization
Background: Portal vein recanalization following portal vein embolization (PVE) can impair future liver remnant (FLR) growth; however, the clinical significance of recanalization and the utility of re‐embolization remain unclear. This study aimed to assess the incidence of recanalization after PVE, its impact on liver regeneration, and the efficacy of re‐embolization. Methods: We retrospectively analyzed 249 consecutive patients who underwent hepatectomy following right PVE between 2010 and 2022. Recanalization was classified as major (section or segment) or minor (less than one segment). In this study, FLR was defined as the left hemiliver for standardization across different surgical procedures. Liver hypertrophy was assessed using the degree of hypertrophy (DH) and the kinetic growth rate (KGR). Re‐embolization was performed in selected patients with insufficient FLR growth due to recanalization. Results: Recanalization occurred in 89 patients (36%), including 55 minor and 34 major recanalizations. DH and KGR differed significantly among the three groups. Subsequent post hoc analysis revealed that major recanalization had significantly lower DH ( p = 0.002) and KGR ( p = 0.003) than non‐recanalization. Seven patients underwent re‐embolization, which significantly improved the FLR ratio (34.2% to 39.8%, p = 0.003) without complications. Conclusions: Major recanalization after PVE was significantly associated with impaired liver regeneration. Re‐embolization is a potentially effective strategy for managing insufficient FLR growth due to recanalization, particularly in cases of major recanalization.
- 13 March 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1309-1319
Open AccessImpact of Recanalization on Liver Hypertrophy after Portal Vein Embolization and the Role of Re‐Embolization
Background: Portal vein recanalization following portal vein embolization (PVE) can impair future liver remnant (FLR) growth; however, the clinical significance of recanalization and the utility of re‐embolization remain unclear. This study aimed to assess the incidence of recanalization after PVE, its impact on liver regeneration, and the efficacy of re‐embolization. Methods: We retrospectively analyzed 249 consecutive patients who underwent hepatectomy following right PVE between 2010 and 2022. Recanalization was classified as major (section or segment) or minor (less than one segment). In this study, FLR was defined as the left hemiliver for standardization across different surgical procedures. Liver hypertrophy was assessed using the degree of hypertrophy (DH) and the kinetic growth rate (KGR). Re‐embolization was performed in selected patients with insufficient FLR growth due to recanalization. Results: Recanalization occurred in 89 patients (36%), including 55 minor and 34 major recanalizations. DH and KGR differed significantly among the three groups. Subsequent post hoc analysis revealed that major recanalization had significantly lower DH ( p = 0.002) and KGR ( p = 0.003) than non‐recanalization. Seven patients underwent re‐embolization, which significantly improved the FLR ratio (34.2% to 39.8%, p = 0.003) without complications. Conclusions: Major recanalization after PVE was significantly associated with impaired liver regeneration. Re‐embolization is a potentially effective strategy for managing insufficient FLR growth due to recanalization, particularly in cases of major recanalization.
- Open Access
- 26 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4143
ASO Visual Abstract: Celiac Axis Stenosis in Pancreatoduodenectomy: Preoperative Predictors for Intervention Considering Stenosis Severity and Collateral Pathway Development
- 26 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4143
Open AccessASO Visual Abstract: Celiac Axis Stenosis in Pancreatoduodenectomy: Preoperative Predictors for Intervention Considering Stenosis Severity and Collateral Pathway Development
- 17 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4126-4127
ASO Author Reflections: Integrating Stenosis Severity and Arcade Development in the Assessment of Celiac Axis Stenosis During Pancreatoduodenectomy
- 17 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4126-4127
ASO Author Reflections: Integrating Stenosis Severity and Arcade Development in the Assessment of Celiac Axis Stenosis During Pancreatoduodenectomy
- Open Access
- 16 February 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1239-1249
Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’
Background: Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods: Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with pathological CR or unresected DLMs without local recurrence. Long‐term outcomes were compared between patients with and without resection of all DLMs. Results: Among 58 patients, 26 (44.8%) had DLMs, totaling 106 lesions. True CR was achieved in 70.8% of DLM lesions. Long‐term outcomes did not differ between patients with and without resection of all DLMs (median recurrence‐free survival, 11.1 vs. 7.6 months, p = 0.594; median surgical failure‐free survival, 11.1 vs. 17.2 months, p = 0.758; median overall survival, 43.6 vs. 53.6 months, p = 0.819). DLM lesions with true CR had smaller initial diameters than those without true CR (5 vs. 9 mm, p = 0.013). Conclusion: Regardless of whether all DLMs were resected, patients had acceptable long‐term outcomes. DLM lesions with a larger initial diameter before chemotherapy may warrant proactive intraoperative exploration for residual disease using contrast‐enhanced ultrasonography.
- 16 February 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1239-1249
Open AccessManagement Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’
Background: Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods: Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with pathological CR or unresected DLMs without local recurrence. Long‐term outcomes were compared between patients with and without resection of all DLMs. Results: Among 58 patients, 26 (44.8%) had DLMs, totaling 106 lesions. True CR was achieved in 70.8% of DLM lesions. Long‐term outcomes did not differ between patients with and without resection of all DLMs (median recurrence‐free survival, 11.1 vs. 7.6 months, p = 0.594; median surgical failure‐free survival, 11.1 vs. 17.2 months, p = 0.758; median overall survival, 43.6 vs. 53.6 months, p = 0.819). DLM lesions with true CR had smaller initial diameters than those without true CR (5 vs. 9 mm, p = 0.013). Conclusion: Regardless of whether all DLMs were resected, patients had acceptable long‐term outcomes. DLM lesions with a larger initial diameter before chemotherapy may warrant proactive intraoperative exploration for residual disease using contrast‐enhanced ultrasonography.